Results 61 to 70 of about 849,373 (191)

Anosmin-1 modulates fibroblast growth factor receptor 1 signaling in human gonadotropin-releasing hormone olfactory neuroblasts through a heparan sulfate-dependent mechanism [PDF]

open access: yes, 2004
Defects of either anosmin-1 or fibroblast growth factor receptor 1 (FGFR1) are known to underlie hereditary Kallmann's syndrome (KS), a human disorder of olfactory and gonadotropin-releasing hormone (GnRH) neuronal ontogeny.
Guimond, S   +17 more
core   +1 more source

Comparative multiplex analysis of cytokines, chemokines and growth factors in follicular fluid of normoresponder women undergoing ovum donation with gonadotropin-releasing hormone agonist versus gonadotropin-releasing hormone antagonist protocols

open access: yesJournal of Human Reproductive Sciences, 2013
Background: Conflicting results were yielded about the superiority of gonadotropin-releasing hormone agonist (GnRH-a) versus gonadotropin-releasing hormone antagonist (GnRH-ant) protocols used in ovarian stimulation in in vitro fertilization (IVF) set-up.
Neena Malhotra   +5 more
doaj   +1 more source

Beliefs about emotions, distress tolerance and paranoia across the menstrual cycle in individuals with premenstrual difficulties and controls

open access: yesBritish Journal of Clinical Psychology, EarlyView.
Abstract Objectives Premenstrual Disorders are characterized by recurrent symptoms associated with clinically significant distress or impairment. There is limited understanding of psychological processes associated with premenstrual difficulties.
Ellen Lambert   +2 more
wiley   +1 more source

Therapeutic access points: The roles of circumventricular organs in drug delivery and metabolic regulation

open access: yesBritish Journal of Pharmacology, EarlyView.
The current obesity drug landscape, dominated by GLP‐1 receptor agonists and emerging multi‐agonist therapies, has reinforced that long‐term weight loss is achieved in large part through central mechanisms that suppress appetite and reshape energy balance.
Ines Martinez‐Corral   +3 more
wiley   +1 more source

Gonadotropin-releasing hormone agonist against severe aggression in autism

open access: yes, 2016
Aggression in patients with autism spectrum disorder (ASD) presents an important therapeutic challenge. Conventional treatment appears to be inadequate in a number of cases.
Helmerhorst, Frans M.   +4 more
core   +1 more source

Interactions of GPR54 and GPR147 receptors with RF-amide ligands [PDF]

open access: yes, 2014
Includes bibliographical references.G protein-coupled receptors play a key role in cellular signaling by transducing extracellular signals via G proteins to elicit intracellular responses.
Hendrikse, Megan
core   +1 more source

Current Approaches to Support Patients to Withdraw From Image and Performance Enhancing Drugs

open access: yesClinical Endocrinology, EarlyView.
ABSTRACT Image and performance‐enhancing drugs (IPEDs) include agents such as androgens, growth hormone, and erythropoietin, which are used to enhance appearance and physical performance. Androgens, also known as anabolic‐androgenic steroids (AAS), are the most used IPEDs worldwide.
Elizabeth Hyams   +3 more
wiley   +1 more source

Perspective on this Article from Effects of Oral Contraceptives or a Gonadotropin-Releasing Hormone Agonist on Ovarian Carcinogenesis in Genetically Engineered Mice

open access: yes, 2009
Perspective on this Article from Effects of Oral Contraceptives or a Gonadotropin-Releasing Hormone Agonist on Ovarian Carcinogenesis in Genetically Engineered ...
Keeley L. Mui (15095043)   +9 more
core   +1 more source

Pattern of prolactin secretion after administration of gonadotropin-releasing hormone agonist at the preovulatory phase of intrauterine insemination cycles

open access: yesSão Paulo Medical Journal
CONTEXT AND OBJECTIVE: Administration of a gonadotropin-releasing hormone (GnRH) agonist at the preovulatory phase is an option for triggering ovulation in assisted reproductive technology cycles.
Mario Cavagna   +7 more
doaj   +1 more source

Weight Regain After Incretin Treatment: The Lean Mass Deficit Hypothesis and a Role for Testosterone Combination Therapy in Men

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs), dual glucose‐dependent insulinotropic polypeptide (GIP)/GLP‐1RA and triple (GIP)/GLP‐1RA/glucagon agonists achieve placebo‐subtracted weight loss of 15% to 22%. Their long‐term value depends on how well the weight loss is maintained and on the composition of weight loss, not only
Michael Zitzmann   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy